<DOC>
	<DOC>NCT01733095</DOC>
	<brief_summary>Portopulmonary hypertension denotes pulmonary hypertension complicating portal hypertension and is present in approximately 5% of cirrhotic patients. Treatment options include prostanoids, sildenafil, and the endothelin-receptor antagonists, bosentan and ambrisentan. This study investigates the safety and efficacy of ambrisentan in portopulmonary hypertension.</brief_summary>
	<brief_title>Ambrisentan for Treatment of Portopulmonary Hypertension</brief_title>
	<detailed_description>Patients with clinically significant PoPH (resting mean pulmonary arterial pressure &gt;25 mm Hg, pulmonary vascular resistance &gt;400 dynes*s*cm-5) will be offered treatment with ambrisentan. Patients will be followed clinically and hemodynamically up to 12 months after start of treatment.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Adult patients with portal hypertension, age &gt;18 years Cirrhosis of any etiology; ChildPugh class A and B Noncirrhotic portal hypertension (e.g. chronic portal vein thrombosis) Informed consent Presence of other causes for pulmonary arterial hypertension History of pulmonary embolism or myocardial infarction within 6 months before study start ChildPugh class C Presence of hepatocellular carcinoma Liver transplantation HIV infection Severe obstructive or restrictive pulmonary disease (predicted FEV1 or VC &lt;65%, respectively) Severe dilated cardiomyopathy (EF &lt;50%) Latent leftheart insufficiency Pregnancy and lactation Esophageal variceal hemorrhage within the last 6 months Refractory ascites Hepatorenal syndrome Persistent hepatic encephalopathy &gt; grade 1 Bilirubin &gt;3.0 mg/dl AST and/or ALT &gt;3x ULN Creatinine &gt;2.0 mg/dl Known hypersensitivity to ambrisentan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>